

CLINICAL TRIAL

NCT03293524 - REFLECT



Neuroophthalmology RED

Efficacy & Safety Study of Bilateral Intravitreal Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT)

Rare Eye Disease concerned by the trial :
Leber Hereditary Optic Neuropathy

Status of the trial: Active, not recruiting
Orphan drug recognition: Yes

Inclusion criteria: [click here to see detailed criteria](#)

Exclusion criteria: [click here to see detailed criteria](#)



Inclusion opening date: 20/12/2018



Inclusion closing date: 30/06/2019

Children



Adults



Within ERN-EYE members



Locations of the trial :

CHNO des XV XX - Centre Hospitalier National d'Ophtalmologie


Paris, France

Moorfields Eye Hospital

London, United Kingdom, EC1V 2PD

Universitair Ziekenhuis Gent

Gent, Belgium



Principal investigators names :

Catherine Vignal (France)

Patrick Yu Wai Man (UK)

Bart Leroy (Belgium)

Funder type : Industry

[More informations](#)